ING Groep NV Sells 8,776 Shares of IQVIA Holdings Inc. (NYSE:IQV)

ING Groep NV lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 37.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,387 shares of the medical research company’s stock after selling 8,776 shares during the period. ING Groep NV’s holdings in IQVIA were worth $2,827,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Blue Trust Inc. raised its position in shares of IQVIA by 266.5% during the 3rd quarter. Blue Trust Inc. now owns 1,030 shares of the medical research company’s stock valued at $244,000 after buying an additional 749 shares in the last quarter. Private Advisor Group LLC boosted its stake in shares of IQVIA by 13.2% during the third quarter. Private Advisor Group LLC now owns 5,746 shares of the medical research company’s stock valued at $1,362,000 after purchasing an additional 668 shares during the period. International Assets Investment Management LLC grew its holdings in shares of IQVIA by 26,871.1% in the third quarter. International Assets Investment Management LLC now owns 40,996 shares of the medical research company’s stock worth $9,715,000 after purchasing an additional 40,844 shares during the last quarter. Brighton Jones LLC increased its stake in IQVIA by 9.4% in the 3rd quarter. Brighton Jones LLC now owns 1,038 shares of the medical research company’s stock worth $246,000 after buying an additional 89 shares during the period. Finally, CENTRAL TRUST Co lifted its holdings in IQVIA by 35.0% during the 3rd quarter. CENTRAL TRUST Co now owns 690 shares of the medical research company’s stock valued at $163,000 after buying an additional 179 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In related news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Stock Performance

Shares of IQV opened at $190.94 on Friday. The stock has a fifty day moving average price of $199.57 and a 200-day moving average price of $216.49. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The firm has a market cap of $33.62 billion, a PE ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IQV shares. TD Cowen dropped their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barclays reduced their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. The Goldman Sachs Group cut their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Truist Financial reaffirmed a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.